Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01266967 · ClinicalTrials.gov registry record · Phase 2
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT01266967 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 172 participants.
The verdict
NCT01266967, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
This study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF V600E or V600K mutation-positive metastatic melanoma to the brain. Subjects in Cohort A will not have received any local brain therapy, and subjects in Cohort B will have received prior local therapy for brain metastases. Subjects will continue on treatment until disease progression, death, or unacceptable adverse event.
Interventions
- DRUG GSK2118436
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01266967
The ClinicalTrials.gov registry entry for NCT01266967 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK2118436 is the first listed.
NCT01266967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01266967 about?
NCT01266967 is a clinical study titled "A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain". This study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF V600E or V600K mutation-positive metastatic melanoma to the brain. Subjects in Cohort A will not have received any local brai...
What is the current status of trial NCT01266967?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2011-02. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01266967?
The interventions under investigation include: GSK2118436 (DRUG).
Who is sponsoring clinical trial NCT01266967?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.